» Articles » PMID: 12426229

Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease

Overview
Specialty Critical Care
Date 2002 Nov 12
PMID 12426229
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

To determine whether patients with fixed airflow obstruction have distinct pathologic and functional characteristics depending on a history of either asthma or chronic obstructive pulmonary disease (COPD), we characterized 46 consecutive outpatients presenting with fixed airflow obstruction by clinical history, pulmonary function tests, exhaled nitric oxide, sputum analysis, bronchoalveolar lavage, bronchial biopsy, and high-resolution computed tomography chest scans. Subjects with a history of COPD (n = 27) and subjects with a history of asthma (n = 19) had a similar degree of fixed airflow obstruction (FEV1: 56 +/- 2 versus 56 +/- 3% predicted) and airway hyperresponsiveness (PC20FEV1: 2.81 [3.1] versus 1.17 [3.3]). Subjects with a history of asthma had significantly more eosinophils in peripheral blood, sputum, bronchoalveolar lavage, and airway mucosa; fewer neutrophils in sputum and bronchoalveolar lavage fluid; a higher CD4+/CD8+ ratio of T cells infiltrating the airway mucosa; and a thicker reticular layer of the epithelial basement membrane. They also had significantly lower residual volume, higher diffusing capacity, higher exhaled nitric oxide, lower high-resolution computed tomography scan emphysema score, and greater reversibility to bronchodilator and steroids. In conclusion, despite similar fixed airflow obstruction, subjects with a history of asthma have distinct characteristics compared with subjects with a history of COPD and should be properly identified and treated.

Citing Articles

Association between platelet/high-density lipoprotein cholesterol ratio and blood eosinophil counts in American adults with asthma: a population-based study.

Zhao Q, Yang P, Li J, Du L, Wang W, Zhu S Lipids Health Dis. 2025; 24(1):67.

PMID: 39984961 PMC: 11846263. DOI: 10.1186/s12944-025-02479-9.


Type 2 inflammation in COPD: is it just asthma?.

Beech A, Higham A, Booth S, Tejwani V, Trinkmann F, Singh D Breathe (Sheff). 2024; 20(3):230229.

PMID: 39534492 PMC: 11555586. DOI: 10.1183/20734735.0229-2023.


Single-Breath Simultaneous Measurement of DL and DL as Predictor of the Emphysema Component in COPD - A Retrospective Observational Study.

Dal Negro R, Turco P, Povero M Int J Chron Obstruct Pulmon Dis. 2024; 19():2123-2133.

PMID: 39351081 PMC: 11439895. DOI: 10.2147/COPD.S467138.


Risk factors for chronic obstructive pulmonary disease (COPD) in a tertiary health institution in Lagos, Nigeria.

Ozoh O, Dede S, Ekete O, Ojo O, Dania M Ghana Med J. 2024; 57(3):175-182.

PMID: 38957678 PMC: 11216736. DOI: 10.4314/gmj.v57i3.3.


A Novel Combined Dry Powder Inhaler Comprising Nanosized Ketoprofen-Embedded Mannitol-Coated Microparticles for Pulmonary Inflammations: Development, In Vitro-In Silico Characterization, and Cell Line Evaluation.

Banat H, Csoka I, Paroczai D, Burian K, Farkas A, Ambrus R Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256908 PMC: 10818896. DOI: 10.3390/ph17010075.